IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides services, such as filling and lyophilization of diagnostic disposables for medical devices; and custom fermentation and purification of enzymes, as well as contract manufacturing. Further, the company makes and sells proteins extracted from botanicals. It serves manufacturers of medical devices, quality control labs, and academic research institutions. The company was founded in 1986 and is based in Montreal, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-514-3444004
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$4.35 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/27/2020 (Estimated)
OptionableNot Optionable
IBEX Technologies (CVE:IBT) Frequently Asked Questions
What is IBEX Technologies' stock symbol?
IBEX Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IBT."
When is IBEX Technologies' next earnings date?
Has IBEX Technologies been receiving favorable news coverage?
Headlines about IBT stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. IBEX Technologies earned a coverage optimism score of -1.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for IBEX Technologies.
Who are some of IBEX Technologies' key competitors?
Some companies that are related to IBEX Technologies include NovaBay Pharmaceuticals (NBY), AorTech International (AOR), Skinbiotherapeutics (SBTX), Hvivo (HVO), Galena Biopharma (SLS), C4X Discovery (C4XD), Realm Therapeutics (RLM), Midatech Pharma (MTPH), Bioxyne (BXN), Anatara Lifesciences (ANR), Collagen Solutions (COS), Tissue Regenix Group (TRX), Living Cell Technologies (LCT), Nuvo Pharmaceuticals (NRI) and Redx Pharma (REDX).
What other stocks do shareholders of IBEX Technologies own?
Who are IBEX Technologies' key executives?
IBEX Technologies' management team includes the folowing people:
- Mr. Paul Baehr, Pres, CEO & Chairman (Age 76)
- Mr. Richard Collin, Director of Fin. & Sec.
- Mr. Claire Bergeron, VP of Admin.
How do I buy shares of IBEX Technologies?
Shares of IBT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is IBEX Technologies' stock price today?
One share of IBT stock can currently be purchased for approximately C$0.14.
How big of a company is IBEX Technologies?
What is IBEX Technologies' official website?
How can I contact IBEX Technologies?
IBEX Technologies' mailing address is 5485 Pare St Suite 100, MONT-ROYAL, QC H4P 1P7, Canada. The company can be reached via phone at +1-514-3444004.
MarketBeat Community Rating for IBEX Technologies (CVE IBT)
MarketBeat's community ratings are surveys of what our community members think about IBEX Technologies and other stocks. Vote "Outperform" if you believe IBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IBT will underperform the S&P 500 over the long term. You may vote once every thirty days.
